Review finds novel technologies enhance bladder cancer diagnosis using urinary DNA methylation biomarkers, suggesting improved clinical applications.
Key Points
Novel technologies enhance early bladder cancer diagnosis through urinary DNA methylation detection, while established genetic biomarkers offer a reliable diagnostic path.
Multiple promising biomarkers and diagnostic models for bladder cancer have been established through various clinical studies, indicating significant advancements in the field.
Traditional detection methods present challenges such as complexity and sample requirement, whereas emerging technologies like CRISPR improve operational efficiency.
The application of microfluidic and digital polymerase chain reaction technologies showcases the potential for reliable urinary DNA methylation detection in clinical settings.